tbuckley/cabot-search huggingface dataset:
P14.03 Meninges metastases in breast cancer-one center study experience of concomitant therapy intrathecal and systemic
Authors: E. Chmielowska, M. Olejniczak
Journal: Neuro-Oncology (2017)

Breast cancer occupies the central nervous system frequently. The treatment is controversial. Therapeutic recommendations depend on the patient’s condition,suggesting only palliative care, or radiotherapy or intrathecal therapy, the systemic therapy on a trial basis.There are different forms of the meninges infiltration: meningitis with the cancer cells in the cerebrospinal fluid or the solid infiltrates, only as enlargment or classical metastases to the meninges. Currently the base of the diagnose is a result of the MR and the clinical symptoms; positive cerebrospinal fluid analysis is not required. Classical meningitis lasts 4 to 11 weeks, while the solid leasion is a chronic disease and can last for many months. We present one-center study experience of concomitant therapy:intrathecal and systemic in the group of patients, in which the spread to meninges was proven without the classical meningitis symptoms. Material: from 2007 to 2015 27 patients with confirmed spread were treated. Overexpression of HER 2 (9 patients) and triple negative (5 patients coexisted with brain metastases, while the luminal B1/A (13 patients) with the bone mets. Except of one case, it was always a multi-organ disease. METHODS:We used liposomal cytarabine. We plan to give 6 intrathecal injections every 14 days, the systhemic therapy depends on the biological subtype and on the former used drugs. We applied: Liposomal doxorubicine (10 patients), Fulvestrant / Aromataze inhibitor (8 patients),Cisplatine (4 patients),Paclitaksel (3 patients) and Lapatinib with Capecytabine (2 patients). The response to treatment was monitored by clinical evaluation and MR. Results: the period between the original diagnose to meninges recurrence took in average 41,3 months. No relation between the frequency of occurence of the meningitis and the subtype of breast cancer was found. . Time to progression was between 2,9 - 189 months. The median survival time is 5,8 months. The longlasting survival of 189 months concerns a patient with luminal B1 subtype.We used liposomal cytarabine injections 73 times, in average 3 injections.. Reason of all premature withdraw was deterioration of patient’s condition. There was no case of withdrawing due to any advers events. The biggest clinical benefit was observed in case of the patients who were treated with Lapatinib and Capecitabine - OS 11-12 months; and those treated with hormonal therapy -OS 6-10 months. An objective response,monitored by MR was confirmed in the group of patients treated with Lapatinib (2 patients) and of those treated with Cisplatine (4 patients). CONCLUSION: The course of the disease depends on the breast cancer’s biological subtype and the efficiency of the applied systemic therapy. The intrathecal therapy should be used as one of the elements of the whole treatment. The combined therapy is well tolerated by patients.
Influenza Vaccination in the First Trimester of Pregnancy and Risk of Autism Spectrum Disorder
Authors: Alberto Donzelli, Alessandro Schivalocchi, Alessandro Battaggia
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Serial Changes in Lamina Cribrosa Depth and Neuroretinal Parameters in Glaucoma
Authors: Jayme R. Vianna, Victoria R. Lanoe, Jack Quach, Glen P. Sharpe, Donna M. Hutchison, Anne C. Belliveau, Lesya M. Shuba, Marcelo T. Nicolela, Balwantray C. Chauhan
Journal: Ophthalmology (2017)
Retrospective analysis of the use of paclitaxel in HIV patients with Kaposi Sarcoma (KS): Institutional experience.
Authors: Adolfo B. Marantz, Bruno Bustos, Eduardo Daniel Adelchanow, Daniel Sergio Lewi, Boris Itkin
Journal: Journal of Clinical Oncology (2015)

e21519 Background: AIDS related Kaposi Sarcoma (AIDS-KS) is one of the most diagnosed types of cancer in patients with HIV, despite the reduction in its incidence with the use of High Activity Antiretroviral Therapy (HAART). The use of Paclitaxel (P) for these patients was evaluated on a Phase III study in first line compared with Liposomal Doxorubicin (LD) and in some Phase II studies in patients who had previously received anthracyclines. The aim of the study is to review our Institution´s experience with patients diagnosed with AIDS-KS with disease progression after LD which received treatment with P. Clinical variables, response, and toxicity were evaluated. Methods: retrospective analysis of the medical records of the patients with diagnose of AIDS-KS who were treated in the Clinical Oncology Service of the Juan Fernandez Hospital in Buenos Aires city-Argentina from year 2000 until 2014 Results: 21 patients with advanced AIDS-KS were treated with P at a dose of 130mg/square meter given intravenously over 3 hours, every 3 weeks. 20 patients were male. Median age at the beginning of treatment was 44 years. All patiens had been previously treated with LD and were receiving HAART. the 6-month response rate was 62% (13/21, 6 complete responses -7 partial responses), 14% (3/21) of patients had stable disease and 24% (5/21) had presented progression during the first 6 months. With a median follow-up of 3.8 years the observed median duration of response to P was 13.1 months. 15% (3/21) of patients presented grade 3-4 toxicity: 2 patients had neutropenia and 1 had neurotoxicity. There was no mortality associated with the treatment. Conclusions: In our experience the use of P in patients with AIDS-KS who showed disease progression with LD proved to be effective with an acceptable toxicity profile. These results are similar with previously reported studies.
tRF/miR-1280 Suppresses Stem Cell–like Cells and Metastasis in Colorectal Cancer
Authors: Bingqing Huang, Huipeng Yang, Xixi Cheng, Dan Wang, Shuyu Fu, Wencui Shen, Qi Zhang, Lijuan Zhang, Zhenyi Xue, Yan Li, Yurong Da, Qing Yang, Zesong Li, Li Liu, Liang Qiao, Ying Kong, Zhi Yao, Peng Zhao, Min Li, Rongxin Zhang
Journal: Cancer Research (2017)

Abstract Several studies have shown that tRNAs can be enzymatically cleaved to generate distinct classes of tRNA-derived fragments (tRF). Here, we report that tRF/miR-1280, a 17-bp fragment derived from tRNALeu and pre-miRNA, influences Notch signaling pathways that support the function of cancer stem-like cells (CSC) in colorectal cancer progression. tRF/miR-1280 expression was decreased in human specimens of colorectal cancer. Ectopic expression of tRF/miR-1280 reduced cell proliferation and colony formation, whereas its suppression reversed these effects. Mechanistic investigations implicated the Notch ligand JAG2 as a direct target of tRF/miR-1280 binding through which it reduced tumor formation and metastasis. Notably, tRF/miR-1280–mediated inactivation of Notch signaling suppressed CSC phenotypes, including by direct transcriptional repression of the Gata1/3 and miR-200b genes. These results were consistent with findings of decreased levels of miR-200b and elevated levels of JAG2, Gata1, Gata3, Zeb1, and Suz12 in colorectal cancer tissue specimens. Taken together, our results established that tRF/miR-1280 suppresses colorectal cancer growth and metastasis by repressing Notch signaling pathways that support CSC phenotypes. Furthermore, they provide evidence that functionally active miRNA can be derived from tRNA, offering potential biomarker and therapeutic uses. Cancer Res; 77(12); 3194–206. ©2017 AACR.
Umbilical Cord Blood Transplantation with Non-TBI Regimens for Advanced Hematological Malignant Diseases
Authors: Nobuaki Nakano, Yoshifusa Takatsuka, Ayumu Kubota, Masahito Tokunaga, Mayumi Tokunaga, Torahiko Makino, Shogo Takeuchi, Atae Utsunomiya
Journal: Blood (2015)
P09.09 Does Temozoloimde improves survival in Pediatric Glioblastoma: A single center analysis
Authors: S. Gupta, S. Mallick
Journal: Neuro-Oncology (2017)

BACKGROUND: Pediatric Glioblastoma (pGBM) is an uncommon entity. The importance of concurrent and adjuvant temozolomide is not known in this subset of patients. METHODS: We retrospectively analyzed our database between 2000 and 2015. All patients were treated with maximally safe surgical resection. This was followed by a uniform treatment schedule of post-operative radiation with concurrent daily temozolomide at 75 mg per meter square. Radiation dose was 60 Gy in 30 fractions planned by 3-dimensional conformal radiotherapy. 4 weeks later, adjuvant temozolomide was started at 150 mg per meter square, day 1 to 5 every 28 days and escalated to 200 mg per meter square if well tolerated. Log-rank test was used to compare survival distribution. The data was analyzed using SPSS v.16. Results: 51 patients were analyzed. Median age was 13 years (Range: 5 to 21 years). 35 males and 16 females were noted. 8 patients had seizures at presentation. Median symptom duration was 3.25 months.29 patients underwent a gross total resection (GTR) while 16 underwent a subtotal resection, 6 patients underwent decompression. 30 patients received concurrent and adjuvant temozolomide. Median PFS was 1.26 years. 1 and 3 year PFS was 54.4% 3 years- 24.6.7%.The median overall survival was 1.45 years. In univariate analysis extent of resection was significantly better favoring GTR (1.45 years vs. 0.96 years; p=0.037) and significance maintained after multivariate analysis p=0.026, HR: 3.069, 95% CI: 1.143-8.238. Survival was better for patients receiving Temozolomide but did not achieve significance, however in multivariate analysis use of Temozolomide was associated with significantly improved survival p=0.036, HR-3.315, 95% CI: 1.078-10.193. Conclusions: GTR improves survival significantly in pGBM. Temozolomide may have a role in pGBM.
OS05.3 Digital Phenotyping: A Novel Method for Quality of Life Assessment in Patients with Brain Tumors
Authors: D. J. Cote, I. Barnett, J. T. Senders, H. Y. Dawood, P. Staples, L. Nayak, J. P. Onnela, T. R. Smith
Journal: Neuro-Oncology (2017)

Introduction: Digital phenotyping (DP) is a novel approach for moment-by-moment quantification of the individual-level human social and behavioral phenotype in-situ using sensor data from personal digital devices. Here, we report the first application of DP in a population of patients with brain tumors. Methods: Participants installed Beiwe, a customizable smartphone application designed for DP, on their phones. The application collects phone sensor and usage data, including GPS, Wi-Fi, accelerometer, Bluetooth, text and call logs, voice recordings, and screen activity, as well as daily pain surveys taken by participants. Patients were enrolled in a general neurosurgical clinic and were included in this study only if they had radiographically- or pathologically-diagnosed brain tumors. A Generalized Estimating Equation (GEE) model was used to test for associations between pain and mobility. Results: A total of 191 person-days of data were collected from 8 patients of whom 38% were men and mean subject age was 54 (range 40–68). Pathology included four pituitary adenomas, two glioblastomas, one low-grade glioma and one meningioma. Daily survey response rate was 48.2% over a median follow-up of 28.5 days. The average daily score for pain was 4.2. Increased mobility in the 24 hours prior to taking a survey was found to be significantly associated with minor pain (as compared to no pain). Pain was significantly associated with four main measures of mobility derived from GPS data. When compared to reporting no pain (0 out of 10), mild pain (1 out of 10) was associated with a 9-fold expected increase in the distance traveled (in meters) in the previous 24 hours. Similarly, patients showed a 14-fold expected increase in radius of gyration traveled, a 9-fold expected increase in maximum diameter traveled, and an 11.5-fold expected increase in maximum distance traveled from home when comparing mild pain to no pain in their previous 24 hours (all p<0.001). Conclusions: Brain tumors can significantly impact patient behavior, functional status, and quality of life. DP is a novel method for evaluating those changes, and highlights associations between subjective pain and objective behavior.
Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance
Authors: Gustavo C. Cerqueira, Ian H. Cheeseman, Steve F. Schaffner, Shalini Nair, Marina McDew-White, Aung Pyae Phyo, Elizabeth A. Ashley, Alexandre Melnikov, Peter Rogov, Bruce W. Birren, François Nosten, Timothy J. C. Anderson, Daniel E. Neafsey
Journal: Genome biology (2017)

Artemisinin-based combination therapies are the first line of treatment for Plasmodium falciparum infections worldwide, but artemisinin resistance has risen rapidly in Southeast Asia over the past decade. Mutations in the kelch13 gene have been implicated in this resistance. We used longitudinal genomic surveillance to detect signals in kelch13 and other loci that contribute to artemisinin or partner drug resistance. We retrospectively sequenced the genomes of 194 P. falciparum isolates from five sites in Northwest Thailand, over the period of a rapid increase in the emergence of artemisinin resistance (2001–2014). We evaluate statistical metrics for temporal change in the frequency of individual SNPs, assuming that SNPs associated with resistance increase in frequency over this period. After Kelch13-C580Y, the strongest temporal change is seen at a SNP in phosphatidylinositol 4-kinase, which is involved in a pathway recently implicated in artemisinin resistance. Furthermore, other loci exhibit strong temporal signatures which warrant further investigation for involvement in artemisinin resistance evolution. Through genome-wide association analysis we identify a variant in a kelch domain-containing gene on chromosome 10 that may epistatically modulate artemisinin resistance. This analysis demonstrates the potential of a longitudinal genomic surveillance approach to detect resistance-associated gene loci to improve our mechanistic understanding of how resistance develops. Evidence for additional genomic regions outside of the kelch13 locus associated with artemisinin-resistant parasites may yield new molecular markers for resistance surveillance, which may be useful in efforts to reduce the emergence or spread of artemisinin resistance in African parasite populations.
Erratum: Corrigendum: Peroxisome proliferation–associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity
Authors: Sabrina Diano, Zhong-Wu Liu, Jin Kwon Jeong, Marcelo O Dietrich, Hai-Bin Ruan, Esther Kim, Shigetomo Suyama, Kaitlin Kelly, Erika Gyengesi, Jack L Arbiser, Denise D Belsham, David A Sarruf, Michael W Schwartz, Anton M Bennett, Marya Shanabrough, Charles V Mobbs, Xiaoyong Yang, Xiao-Bing Gao, Tamas L Horvath
Journal: Nature Medicine (2011)
A Novel BRD4 Inhibitor CA2 Suppresses MM Cell Proliferation in an Orthotopic Myeloma Mouse Model
Authors: Natsuki Imayoshi, Makoto Yoshioka, Susumu Nakata, Jay Chauhan, Yoko Kado, Yuki Toda, Steven Fletcher, Jeffrey Strovel, Kazuyuki Takata, Eishi Ashihara
Journal: Blood (2016)
P09.46 Accurate prediction of survival in Glioblastoma Multiforme. A machine learning tool
Authors: A. Ruiz-Patino
Journal: Neuro-Oncology (2017)

Introduction: Survival for patients with Glioblastoma Multiforme despite novel therapies remains poor. Accurate prediction tools can identify patients who can benefit from intensive treatment and others in whom the risks outweigh the gains. The rationale of this present study is to conceive a decision making tool to help clinicians determine the prognosis of patients with the most frequent central nervous system tumor in the adult. Materials and Methods: Data from a retrospective cohort of 41 patients was employed to train and validate a machine learning tool based on artificial neural networks. Training variables were: Age at diagnosis, Karnofsky Performance Index, MGMT methylation status and EGRF expression status. Primary prediction endpoint was survival status at 12 months. 70% of patients were randomly selected to the training of the tool and the remaining 30% to the validation. Once the tool was constructed with the training data, data from the validation patients was inputed and the results compared against the cohort data. Operational characteristics and a ROC were calculated. Finally, to further validate the tool, a survival analysis in the validation set between the patients, expected to be survivors and non-survivors at 12 months by the tool, was conducted. Results: The overall performance of the prediction tool reached a sensitivity of 100% and a specificity of 93% with an Area Under the Curve of 0.988 for the accurate prediction of survival status at 12 months. When survival between the expected survivors and non-survivors identified by the tool was compared, a statistical significant result (p &lt 0.001) between the two groups favoring the expected survivors was obtained. Conclusions: Machine learning algorithms can be a very helpful and powerful tool to predict survival in patients with glioblastoma multiforme. A larger prospective cohort could be analyzed to obtain robust findings that can be incorporated into clinical practice and help decision making.
Laparoscopic Splenectomy for Immune Thrombocytopenic Purpura (ITP): A Single Center Experience
Authors: Silvia Cantoni, Dario Maggioni, Valentina Mancini, Anna Brizio, Maddalena Mazzucchelli, Carmelo Magistro, Annamaria Nosari, Raffaele Pugliese, Enrica Morra
Journal: Blood (2008)
Der f 35: An <scp>MD</scp>‐2‐like house dust mite allergen that cross‐reacts with Der f 2 and Pso o 2
Authors: T. Fujimura, T. Aki, T. Isobe, A. Matsuoka, T. Hayashi, K. Ono, S. Kawamoto
Journal: Allergy (2017)

Abstract Background Dermatophagoides farinae is a source of airborne house dust mite ( HDM ) allergens. We elucidated IgE‐reactive allergens from D. farinae by two‐dimensional immunoblotting‐based allergenome analysis, and identified one new allergen, named Der f 35, that possesses IgE‐binding capacity comparable to that of Der f 2. The aim of this study was to clarify the allergenic capacity of new HDM allergen Der f 35. Methods We cloned der f 35 from D. farinae mRNA and produced recombinant Der f 35 in Escherichia coli . The IgE‐binding capacity of Der f 35 and its cross‐reactivity with group 2 allergens from D. farinae and Psoroptes ovis were determined by enzyme‐linked immunosorbent assay (ELISA) and ELISA inhibition assays, respectively. Results The deduced amino acid sequence for der f 35 , which possesses the MD ‐2‐related lipid‐recognition domain, showed higher identity with group 2 allergens from P. ovis (61.5%) and Blomia tropicalis (50.7%) than with Der f 2 (40.8%). Der f 35 showed IgE‐binding frequencies of 77.5% (31/40) for the native form upon allergenome analysis and 51.4% (18/35) for recombinant structure by ELISA . Der f 35 showed cross‐reactivity with Der f 2 and Pso o 2 in reaction with HDM ‐allergic patients' IgE by ELISA inhibition assay. Conclusion Der f 35 is a candidate major allergen from D. farinae , which is more similar to group 2 allergens from sheep scab mite and storage mites. Der f 35 could be responsible for the cross‐reactivity among group 2 mite allergens.
P12.01 Active beam scanning proton therapy for intracranial meningiomas: early treatment outcomes from Trento proton therapy center
Authors: D. Amelio, D. Scartoni
Journal: Neuro-Oncology (2017)

PURPOSE: To report preliminary results of active beam scanning proton therapy (PT) for intracranial meningiomas. MATHERIAL/METHODS: Twenty patients (pts) with meningiomas (histologically proven 16/20) were treated with PT between January 2015 and October 2016. Median age was 63 years (range, 43-82) while KPS ranged between 60 and 100 (median 80); 16 were female (80%), and 4 were male (20%). For patients who underwent surgery, 6 patients had a diagnosis of World Health Organization (WHO) Grade I, 6 of WHO grade II, and 4 of a WHO Grade III. In 4 patients diagnosis was based on the typical imaging appearance of a benign meningioma. All but one pts with grade II/III lesions had a tumor pattern of meningiomatosis. Thirteen (65%) pts had skull base lesions. For benign meningiomas, total doses of 50 - 54 Gy(relative biologic effectiveness [RBE]) were applied. Grade II lesions, were treated with 60 GyRBE while grade III tumors received a boost up to 66 GyRBE in case of gross residual tumor. Four patients were treated as re-irradiation (range, 50.4-66 GyRBE). All the treatments were delivered at 1.8-2 GyRBE per fraction. All pts were treated with active beam scanning PT using 3-4 fields with single field optimization technique. Treatment planning was based on MRI. Eleven pts (55%) received also 68-Ga-DOTATOC-PET. Gross tumor volume ranged from 1 to 61 cc, while clinical target volume varied between 2 and 195 cc. Toxicity was assessed according to Common Terminology Criteria for Adverse Events version 4.0. Mean follow-up time was 6 months (range, 1-21). Results: All pts completed the treatment without breaks. Registered acute side effects include grade 1 (15%) and grade 2 (20%) skin erythema, grade 2 (25%) alopecia, grade 1 (55%) fatigue, grade 1 (10%) and grade 2 (5%) conjunctivitis, grade 1 (15%) pain, grade 1 (15%) blurred vision, grade 1 (30%) headache, and grade 2 (10%) skin hyperpigmentation. There were no grade 3 or higher acute toxicities. Registered late side effects include grade 1 (5%) and grade 2 (30%) alopecia, grade 1 (10%) and grade 2 (10%) fatigue, grade 1 (15%) and grade 2 (5%) headache, grade 1 (5%) dizziness, grade 1 (10%) blurred vision, grade 1 (5%) and grade 2 (5%) pain, grade 1 (5%) dry eye, and grade 1 (10%) skin hyperpigmentation. During follow-up one pts (5%) who previously underwent 3 surgeries and 3 stereotactic radiation treatments developed radionecrosis (diagnosed at imaging) with no symptoms and no need of steroids. There were no grade 3 or higher late toxicities. Currently, absolute tumor control is 95%. One WHO III pts who previously underwent 2 surgeries and 1 stereotactic radiation treatment presented with both local and systemic tumor recurrence 5 months after PT. Conclusions: PT is feasible and safe treatment for pts with untreated, recurrent, or incompletely resected intracranial meningiomas. Longer follow-up is necessary to assess definitive efficacy.